Rein Therapeutics (RNTX) Invested Capital (2016 - 2025)
Rein Therapeutics (RNTX) has disclosed Invested Capital for 10 consecutive years, with $46.2 million as the latest value for Q3 2025.
- On a quarterly basis, Invested Capital fell 51.5% to $46.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $46.2 million, a 51.5% decrease, with the full-year FY2024 number at $54.4 million, down 44.67% from a year prior.
- Invested Capital was $46.2 million for Q3 2025 at Rein Therapeutics, down from $48.0 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $101.0 million in Q2 2024 to a low of $11.2 million in Q3 2023.
- A 5-year average of $49.5 million and a median of $48.0 million in 2025 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: crashed 60.47% in 2023, then skyrocketed 750.44% in 2024.
- Rein Therapeutics' Invested Capital stood at $43.9 million in 2021, then crashed by 57.58% to $18.6 million in 2022, then soared by 427.83% to $98.3 million in 2023, then tumbled by 44.67% to $54.4 million in 2024, then decreased by 15.08% to $46.2 million in 2025.
- Per Business Quant, the three most recent readings for RNTX's Invested Capital are $46.2 million (Q3 2025), $48.0 million (Q2 2025), and $49.9 million (Q1 2025).